Levente Meszaros
Corporate Officer/Principal at RADIOPHARM THERANOSTICS LIMITED
Profile
Levente Meszaros has worked as a Director of Technical Operations at NanoMab Technology Ltd.
and is currently working as a Global Director of Translational Science at Radiopharm Theranostics Ltd.
Levente Meszaros active positions
| Companies | Position | Start |
|---|---|---|
| RADIOPHARM THERANOSTICS LIMITED | Corporate Officer/Principal | 2021-12-31 |
NanoMab Technology Ltd.
 NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | Chief Tech/Sci/R&D Officer | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| RADIOPHARM THERANOSTICS LIMITED | Health Services |
| Private companies | 1 |
|---|---|
NanoMab Technology Ltd.
NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | Health Technology |
- Stock Market
- Insiders
- Levente Meszaros
